MRSA pneumonia
MRSA in the lungs behaves in two very different ways: a slow hospital infection in ventilated patients, and an explosive necrotising pneumonia that follows influenza in healthy young people. This is how to tell them apart, and what treatment involves.
The short answer
MRSA pneumonia is a lung infection caused by methicillin-resistant Staphylococcus aureus. Most cases occur in hospital, in people who are ventilated or recently unwell. A smaller but far more dangerous group occurs in the community, usually days after influenza, and is caused by toxin-producing CA-MRSA strains that destroy lung tissue. Both are medical emergencies treated with intravenous antibiotics — usually vancomycin or linezolid.
The two forms of MRSA pneumonia
Separating these matters, because the patients, the speed, and the outlook are completely different.
Hospital-acquired and ventilator-associated MRSA pneumonia
This is the commoner form. MRSA colonising the nose or throat is aspirated into the lungs, often past an endotracheal tube. It appears 48 hours or more after admission, presents with new fever, purulent secretions, worsening oxygenation, and new shadowing on imaging. Mortality is around 30%, driven as much by the patient's underlying illness as by the organism itself.
Community-associated necrotising MRSA pneumonia
Caused mainly by CA-MRSA strains carrying the Panton-Valentine leukocidin (PVL) toxin, this form strikes previously healthy children and young adults, classically 3 to 7 days after influenza or another viral illness. PVL destroys neutrophils and lung tissue, producing cavities, haemoptysis, and rapid respiratory failure. Mortality reaches 40 to 60%.
Empyema and lung abscess
MRSA pneumonia can spill infection into the pleural space (empyema) or wall off a cavity of pus within the lung (abscess). Both cause persistent fever despite antibiotics and both need drainage — a chest drain for empyema, sometimes surgery for a large abscess. Antibiotics alone rarely clear them.
Septic pulmonary emboli
In MRSA bloodstream infection — particularly right-sided endocarditis in people who inject drugs — clumps of infected material shower into the lungs, producing multiple small peripheral nodules that cavitate. Treatment targets the bloodstream source rather than the lungs alone.
Symptoms
- High fever, chills and sweats
- Cough producing thick yellow, green or blood-stained sputum
- Breathlessness at rest and rapid, shallow breathing
- Sharp chest pain that worsens on breathing in
- Confusion, drowsiness or agitation as oxygen levels fall
- In necrotising pneumonia: coughing up frank blood and collapse within hours
How it is diagnosed
Imaging comes first — a chest X-ray or CT showing consolidation, and in necrotising disease cavities within the affected lobe. Microbiology confirms the organism: sputum culture, tracheal aspirate or bronchoalveolar lavage in ventilated patients, plus blood cultures to check whether MRSA has reached the bloodstream. A rapid nasal or respiratory PCR can flag MRSA within hours, and susceptibility testing then confirms which antibiotics will work. See how MRSA testing works.
Treatment
Intravenous vancomycin and linezolid are the first-line agents. Linezolid is often favoured in necrotising disease because it reaches lung tissue well and suppresses PVL toxin production; clindamycin is sometimes added for the same reason. Ceftaroline and telavancin are alternatives when patients cannot tolerate the first-line drugs.
Antibiotics alone are not enough. Oxygen, non-invasive support or mechanical ventilation, drainage of empyema, and management of the underlying influenza or sepsis all determine the outcome. Courses typically run 7 to 21 days, longer where there is cavitation or bacteraemia. Read more about MRSA treatment options.
Outlook and recovery
Hospital-acquired MRSA pneumonia carries roughly 30% mortality, largely reflecting how unwell affected patients already are. Community necrotising pneumonia kills 40 to 60% even with intensive care, and survivors may be left with scarred lungs and reduced exercise tolerance. Fatigue and breathlessness commonly persist for one to three months after discharge.
Red flags — call emergency services
- Breathlessness at rest, or unable to complete a sentence
- Coughing up blood, especially after a flu-like illness
- Blue or grey lips or fingertips
- Confusion, collapse, or a very low blood pressure reading
- Fever with rapid deterioration over hours rather than days
Related
MRSA pneumonia is one of several invasive MRSA conditions. It often coexists with MRSA bacteremia and can progress to MRSA sepsis.
Frequently asked questions
- CDC. Methicillin-resistant Staphylococcus aureus (MRSA): clinical overview (2024)
- IDSA / ATS. Management of adults with hospital-acquired and ventilator-associated pneumonia (2016)
- NHS. Pneumonia — symptoms, causes and treatment (2024)
- World Health Organization. Antimicrobial resistance: global report on surveillance (2023)
Symptoms hub
Overview of MRSA symptoms and day-by-day progression.
What does MRSA look like?
Bumps, boils, abscesses and cellulitis — every visual form.
MRSA skin infection
Types, diagnosis, treatment, and when skin MRSA becomes dangerous.
MRSA bacteremia
MRSA in the bloodstream — how it gets there and how it's treated.
MRSA sepsis
Can MRSA cause sepsis? Warning signs and survival rates.
Invasive MRSA
How MRSA reaches the bloodstream, lungs and bone.
MRSA test
PCR nasal swab, wound culture and susceptibility testing.
MSSA vs MRSA
Same bacterium, different antibiotic susceptibility.